Antisense Oligonucleotides Targeted to Human CDC45
- Summary
- Antisense oligonucleotides that inhibit expression of human replication-initiation protein as well as methods of preventing or treating hyperproliferative conditions using said oligonucleotides are introduced.
One aspect provides an antisense oligonucleotides that inhibits the expression of human replication-initiation protein and has a sequence complementary to at least a portion of a target sequence encoding a human replication initiation gene. By administering a therapeutically effective amount of antisense oligonucleotides or by contacting the hyperproliferating cells with an effective amount of antisense oligonucleotides, expression of replication-initiation protein is inhibited. Methods of screening and testing active antisense oligonucleotides for their ability to inhibit gene expression are also introduced.
- Technology Benefits
- 1. Inhibition of DNA replication thus cancer cells growth can be inhibited and can be killed
2. Have little side effect
3. Without inhibiting the metabolism and functions of non-dividing normal cells
4. Comprehensive
5. Relatively low cost
6. Efficient
- Technology Application
- - Clinical trials for the development of new effective anticancer drugs
- Useful for the development of antisense oligonucleotides as medicine
- Supplementary Information
- Patent Number: US7393950B2
Application Number: US2002232923A
Inventor: Liang, Chun | Feng, Dao-rong | Yu, Zhi-ling
Priority Date: 29 Aug 2002
Priority Number: US7393950B2
Application Date: 29 Aug 2002
Publication Date: 1 Jul 2008
IPC Current: C07H002104 | A61K003170 | C12N0015113 | A61K003800
US Class: 5360245 | 514044
Assignee Applicant: The Hong Kong University of Science & Technology
Title: Antisense oligonucleotides targeted to human CDC45
Usefulness: Antisense oligonucleotides targeted to human CDC45
Summary: A method comprising administering to a human or cells an antisense oligonucleotide above, where expression of the replication-initiation protein is inhibited, is useful for treating or preventing a hyperproliferative condition (claimed) such as cancer, angiogenesis or neovascularization, psoriasis, blood vessel restenosis, or atherosclerosis. The antisense oligonucleotides are useful for research purposes such as assays, purification, cellular product preparations and other methodologies. The antisense oligonucleotides are also useful for detecting and diagnosing human replication-initiation protein expression.
Novelty: New antisense oligonucleotides comprising a sequence complementary to a target sequence encoding at least a portion of mRNA of a human replication-initiation gene, useful for treating or preventing e.g., cancer and angiogenesis
- Industry
- Disease Diagnostic/Treatment
- Sub Category
- Cancer/Tumor
- Application Date
- 29 Aug 2002
- Application No.
- US 10/232923
- Patent Information
- US 7393950
- ID No.
- TTC.PA.157
- Country/Region
- Hong Kong
For more information, please click Here
